WO2010009589A1 - Use of hydrochloric acid for the manufacture of a medicament for treatment of gastritis, enteritis and angiitis - Google Patents

Use of hydrochloric acid for the manufacture of a medicament for treatment of gastritis, enteritis and angiitis Download PDF

Info

Publication number
WO2010009589A1
WO2010009589A1 PCT/CN2008/071708 CN2008071708W WO2010009589A1 WO 2010009589 A1 WO2010009589 A1 WO 2010009589A1 CN 2008071708 W CN2008071708 W CN 2008071708W WO 2010009589 A1 WO2010009589 A1 WO 2010009589A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydrochloric acid
enteritis
gastritis
vasculitis
medicament
Prior art date
Application number
PCT/CN2008/071708
Other languages
French (fr)
Chinese (zh)
Inventor
刘智仁
Original Assignee
Liu Zhiren
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liu Zhiren filed Critical Liu Zhiren
Priority to PCT/CN2008/071708 priority Critical patent/WO2010009589A1/en
Publication of WO2010009589A1 publication Critical patent/WO2010009589A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Definitions

  • hydrochloric acid in the preparation of medicaments for treating gastritis, enteritis and vasculitis
  • the present invention relates to the use of hydrochloric acid in the preparation of a medicament for the treatment of gastritis, enteritis and vasculitis.
  • Salmonella parahaemolyticus halophilic bacteria
  • Helicobacter pylori certain influenza viruses and enteroviruses.
  • the golden staphylococcal toxin is the most common.
  • Salmonella is often grown in meat and eggs.
  • Vibrio parahaemolyticus is mainly used in crab, fish, snails, sea bream and other seafood pickles. The food is long-lasting, milk and meat are suitable for staphylococcal reproduction and enterotoxin production.
  • Thromboangiitis obliterans referred to as vasculitis
  • vasculitis is a slow-moving, mainly vascular lesion involving the small arteries and veins of the extremities.
  • Pathological changes are staged, non-suppurative inflammation of the vessel wall with intraluminal thrombosis
  • prostaglandin E has the effects of relaxing blood vessels and inhibiting platelet aggregation.
  • Such as prostate dysfunction or during the young adult, frequent sexual life causes prostaglandins to be lost with semen, resulting in a corresponding decrease in prostaglandins, which may cause peripheral vasomotor dysfunction, thrombosis, secondary inflammation.
  • trauma trauma caused by vascular injury, or stimulation of nerve receptors due to trauma, which in turn causes central nervous system dysfunction, which gradually loses its regulation of blood vessels, causing vasospasm, long-term paralysis and thrombosis.
  • vasculitis often uses vasodilator drugs and anti-inflammatory drugs. Because the medical community's formation mechanism of vasculitis is not clear, the medication can only relieve symptoms to a certain extent and cannot be cured.
  • the technical problem to be solved by the invention is to provide a use of hydrochloric acid in the preparation of a medicament for treating gastritis.
  • the technical problem to be solved by the present invention is to provide a use of hydrochloric acid in the preparation of a medicament for treating gastritis.
  • the technical problem to be solved by the present invention is to provide a use of hydrochloric acid in the preparation of a medicament for treating enteritis.
  • the technical problem to be solved by the present invention is to provide a use of hydrochloric acid in the preparation of a medicament for treating vasculitis.
  • gastritis, enteritis, and vasculitis are based on the following mechanisms: Food is digested in the stomach, producing large amounts of organic acids, carbonic acid, and hydrogen ions (H+), collectively referred to as gastric acid. . Mucus and lipid membrane surface of the gastric parietal cells of the stomach carbonate adsorption (H 2 C0 3), an inorganic acid forming the protective layer, the protective layer protects the stomach from gastric digestion of food organic acids produced inch erosion.
  • the mucus and lipids on the intestinal wall absorb the carbonic acid (H 2 C0 3 ) in the intestine to form a protective layer of inorganic acid; the mucus and lipids on the blood vessel wall adsorb carbonic acid (H 2 C0 3 ) in the blood vessel. , forming a protective layer of inorganic acid.
  • Atrophic gastritis is formed by erosion.
  • the erosion of the intestinal wall by organic acids causes enteritis, and the erosion of the blood vessel wall by organic acids causes vasculitis.
  • hydrochloric acid is the most ideal material for forming a protective layer of inorganic acid.
  • hydrochloric acid is a strong inorganic acid, and the ability of mucus and lipid substances on the stomach wall, intestinal wall and blood vessel wall to adsorb hydrochloric acid is much better than adsorption of carbonic acid.
  • the inorganic acid can protect the body, and the conclusion that the organic acid erodes the body can be explained from the following: An aqueous solution containing a mineral acid (hydrochloric acid) and an aqueous solution containing an organic acid (such as acetic acid) (the pH of the aqueous solution is equal)
  • An aqueous solution containing a mineral acid (hydrochloric acid) and an aqueous solution containing an organic acid (such as acetic acid) the pH of the aqueous solution is equal
  • the skin is scrubbed separately, and the aqueous solution of inorganic acid moisturizes the skin to protect the skin. After scrubbing several times with an aqueous solution of organic acid, the skin is roughened. This can explain to some extent that when the organic acid directly contacts the human body surface, the inner wall of the organ and the inner wall of the blood vessel, it will be eroded and destroyed, while the inorganic acid can protect it.
  • the hydrochloric acid of the present invention is used for preparing a drug for treating gastritis, enteritis, and vasculitis.
  • the drug is an aqueous solution containing hydrochloric acid.
  • the pH of the aqueous solution is controlled at 1.5 to 6.9, and more preferably The pH of the aqueous solution is controlled to be 4 to 6.5.
  • the pH of the aqueous solution is controlled to be 6.5 to 6.9. According to the national drinking water standard, the pH of drinking water should be 6.5 to 8.5. Therefore, as long as the pH of the aqueous solution is controlled to be 6.5 to 6.9, the aqueous solution containing hydrochloric acid can be directly consumed as edible hydrochloric acid water.
  • the drugs can be used for the preparation of oral liquid or injection and other dosage forms, as a therapeutic aqueous solution of hydrochloric acid in the treatment of gastritis, enteritis, vasculitis, daily drinking is generally controlled at 1000 ⁇ 3000ml, divided into 3 ⁇ 6 times to drink, 3 to 6 months for a course of treatment.
  • the recommended daily dose is 500ml, divided into two injections, intravenous drip, for 2 to 3 months for a course of treatment.
  • gastroenteritis, enteritis and vasculitis can be treated. After one year, the general dose can be halved, and after two years, basic rehabilitation.
  • the oral solution can be artificially prepared as follows: Hydrochloric acid is added to the drinking water and stirred evenly. The pH value is accurately detected before filling and sterilizing, and the pH is controlled at 1.5 to 6.9; the pH of the edible hydrochloric acid is controlled at 6.5 to 6.9.
  • a pH control device can be used to continuously, stably and in large quantities prepare the above aqueous solution containing hydrochloric acid.
  • An injection can be prepared from hydrochloric acid in a pharmaceutically usual manner as long as the pH of the injection is controlled to be 1.5 to 6.9.
  • Hydrochloric acid hydrazine is made from tap water.
  • a purification device should be installed at the front end to meet the national sanitary standard for drinking water.
  • the hydrochloric acid of the present invention can also be applied to other solutions, such as physiological saline, glucose solution, beverage, etc., and the method for preparing hydrochloric acid water is the same as above, as long as control
  • the pH of the oral solution or the injection can be used.
  • the edible hydrochloric acid water according to the present invention generally does not allow heating to be consumed, because heating causes the hydrochloric acid to volatilize and loses its therapeutic effect. Do not drink beverages, tea and alkaline health products that are prone to scaling. Theophylline and alkaline substances are easily neutralized with hydrochloric acid to disable the aqueous hydrochloric acid solution.
  • the present invention has clinically observed 1060 patients with gastritis and enteritis drinking drinking hydrochloric acid, wherein 500 patients with gastritis, enteritis 400 patients, 160 patients with vasculitis, 560 males and 500 females, with an average age of 59 years, age range 28 ⁇ 7
  • the medicament prepared by the hydrochloric acid preparation of the invention is safe and reliable for treating gastritis, enteritis and vasculitis, and has a certain and obvious effect.
  • Table 1 shows the improvement of gastritis in cases after drinking the edible hydrochloric acid water of the present invention.
  • Table 2 shows the improvement of enteritis in cases after drinking the edible hydrochloric acid water of the present invention.
  • Table 3 shows the improvement of vasculitis in cases after drinking the edible hydrochloric acid water of the present invention.
  • vasculitis 74 Significant relief after two years From Table 1, Table 2, Table 3, it can be seen that the aqueous solution of hydrochloric acid is effective in the treatment of gastritis, enteritis and vasculitis, and the total effective rate is 100%.

Abstract

Use of hydrochloric acid for the manufacture of a medicament for the treatment of gastritis, enteritis and angiitis. Said medicament is usually an aqueous solution comprising hydrochloric acid. The pH of the solution is controlled in the range of 1.5-6.9.

Description

说明书 盐酸在制备治疗胃炎、 肠炎和脉管炎药物中的应用 技术领域  Application of hydrochloric acid in the preparation of medicaments for treating gastritis, enteritis and vasculitis
[1] 本发明涉及盐酸在制备治疗胃炎、 肠炎和脉管炎药物中的应用。  [1] The present invention relates to the use of hydrochloric acid in the preparation of a medicament for the treatment of gastritis, enteritis and vasculitis.
背景技术  Background technique
[2] 胃炎、 肠炎、 脉管炎的形成机理, 目前整个医学界尚未有定论。 如现代医学认 为急慢性胃肠炎的发病可能与下列因素有关:  [2] The formation mechanism of gastritis, enteritis, and vasculitis has not yet been determined in the medical community. For example, modern medicine believes that the onset of acute and chronic gastroenteritis may be related to the following factors:
[3] 一、 感染因素  [3] First, the infectious factors
进食被细菌或其毒素污染的食物。 常见的致病细菌有沙门氏菌属副溶血弧菌 ( 嗜盐菌) 幽门螺旋杆菌, 以及某些流感病毒和肠道病毒等。 毒素中以金黄色葡 萄球菌毒素为最常见。 沙门氏菌属常在肉、 及蛋中生长。 副溶血弧菌主要在蟹 、 鱼、 螺、 海蜇等海产品咸菜中, 天热久置的饭菜, 奶、 肉食适宜于葡萄球菌 繁殖及肠毒素的产生。  Eat food contaminated with bacteria or their toxins. Common pathogenic bacteria are Salmonella parahaemolyticus (halophilic bacteria) Helicobacter pylori, and certain influenza viruses and enteroviruses. Among the toxins, the golden staphylococcal toxin is the most common. Salmonella is often grown in meat and eggs. Vibrio parahaemolyticus is mainly used in crab, fish, snails, sea bream and other seafood pickles. The food is long-lasting, milk and meat are suitable for staphylococcal reproduction and enterotoxin production.
[4] 二、 理化因素  [4] Second, physical and chemical factors
物理因素如进食过热、 过冷粗糙的食物, X线照射等。 化学因素如烈酒咖啡、 浓 茶、 香料及某些药品均可损伤胃粘膜, 引起炎症性改变。  Physical factors such as eating overheated, cold and rough food, X-ray irradiation, etc. Chemical factors such as spirits, strong tea, spices and certain drugs can damage the gastric mucosa and cause inflammatory changes.
[5] 三、 其他  [5] Third, other
暴饮暴食、 过度疲劳、 受凉等使机体抵抗力下降或胃粘膜屏障遭受破坏, 易于 受以上因素侵袭而发病。  Overeating, excessive fatigue, cold, etc., reduce the body's resistance or damage the gastric mucosal barrier, and are prone to attack by the above factors.
[6] 得了胃肠病一般釆用饥饿疗法, 降低胃酸法, 消炎杀菌法等, 无论釆用哪种方 法都难以根治肠、 胃病。 [6] It is common to use hunger therapy for gastrointestinal diseases, reduce gastric acid method, anti-inflammatory bactericidal method, etc. It is difficult to cure intestinal and stomach diseases regardless of the method used.
[7] 血栓闭塞性脉管炎简称脉管炎, 是一种进行缓慢的、 主要累及四肢中小动脉和 静脉的血管病变。 病理变化为血管壁的阶段性、 非化脓性炎症伴腔内血栓形成[7] Thromboangiitis obliterans, referred to as vasculitis, is a slow-moving, mainly vascular lesion involving the small arteries and veins of the extremities. Pathological changes are staged, non-suppurative inflammation of the vessel wall with intraluminal thrombosis
, 管腔阻塞, 导致肢体缺血, 引起疼痛和肢端坏疽。 病程呈周期性发作, 病变 多在下肢。 好发于 20-40岁的男性。 属于中医"脱疽"范畴。 目前对脉管炎的发病 原因尚不明确, 医学认为主要与以下因素有关: The lumen is blocked, causing limb ischemia, causing pain and gangrene of the extremities. The course of the disease is periodic, and the lesions are mostly in the lower limbs. Occurs in men aged 20-40. It belongs to the category of "dislocation" of Chinese medicine. At present, the cause of vascular inflammation is still unclear. Medicine believes that it is mainly related to the following factors:
[8] 1、 吸烟: 综合国内资料, 血栓闭塞性脉管炎有吸烟史者占 60%--95%。 烟草含 有尼古丁可引起小血管痉挛, 产生血管损害。 Erb等曾用烟草浸出液进行动物实 验能引起血管病变。 Harkary等用烟草浸出液作皮试, 发现血栓闭塞性脉管炎病 人的阳性率 (78%--87%) 明显高于正常人 (16%-46%) 。 [8] 1, smoking: Comprehensive domestic data, thromboangiitis obliterans have a history of smoking accounted for 60% -95%. Tobacco Nicotine can cause small blood vessels to sputum and cause vascular damage. Erb et al. have used tobacco extracts for animal experiments to cause vascular lesions. Harkary other tobacco leachate skin test, the positive rate was found thromboangiitis obliterans patients (7 8% --87%), significantly higher than normal (16% --46%).
2、 性激素: 本病多发于青年男性, 国内外报道占 97.5%_98.2%。 据报道, 前 列腺素 E有舒张血管、 抑制血小板聚集等作用。 如前列腺功能紊乱或在青壮年吋 期, 频繁的性生活使前列腺素随精液而大量丢失, 以致前列腺素相应减少, 就 有可能促使周围血管舒缩失常, 血栓形成, 继发炎症。  2, sex hormones: The disease occurs mostly in young men, domestic and foreign reports accounted for 97.5% _ 98.2%. It has been reported that prostaglandin E has the effects of relaxing blood vessels and inhibiting platelet aggregation. Such as prostate dysfunction or during the young adult, frequent sexual life causes prostaglandins to be lost with semen, resulting in a corresponding decrease in prostaglandins, which may cause peripheral vasomotor dysfunction, thrombosis, secondary inflammation.
3、 寒冻、 潮湿: 据国内资料统计, 有寒冻史者占 57.9%。 长期寒冷刺激血管痉 挛, 致使血管炎症变性, 内膜增生变厚以及血栓形成。  3. Cold and humid: According to domestic statistics, there are 57.9% of those with a history of cold. Long-term cold stimulates vasospasm, causing degeneration of vascular inflammation, thickening of intimal hyperplasia, and thrombosis.
4、 外伤: 外伤引起血管损伤, 或因外伤刺激神经感受器, 进而引起中枢神经 功能失调, 使其逐渐丧失对血管的调节作用, 引起血管痉挛, 长期痉挛而导致 血栓阻塞。  4, trauma: trauma caused by vascular injury, or stimulation of nerve receptors due to trauma, which in turn causes central nervous system dysfunction, which gradually loses its regulation of blood vessels, causing vasospasm, long-term paralysis and thrombosis.
5血液凝固性增高因素: 血栓闭塞性脉管炎病人全血黏度和血浆黏度增高, 红 细胞电泳吋间减慢、 血小板聚集性增高, 但在发病机理上, 血液与血管之间的 因果关系, 尚有待研究。  5 factors of blood coagulation increase: thrombus occlusive vasculitis patients with increased blood viscosity and plasma viscosity, red blood cell electrophoresis, sputum slowing, increased platelet aggregation, but in the pathogenesis, the causal relationship between blood and blood vessels, still To be studied.
6、 免疫学说: 近年来研究显示, 血栓闭塞性脉管炎病人有特殊的抗体存在。 有学者认为本病是在烟草过敏和其他因素的反复作用下的一种自身免疫性疾病  6, immunology: In recent years, studies have shown that patients with thromboangiitis obliterans have special antibodies. Some scholars believe that this disease is an autoimmune disease under the repeated action of tobacco allergy and other factors.
目前治疗脉管炎多釆用扩血管药物和消炎药。 由于医学界对脉管炎的形成机理 并不清楚, 所以用药也只能在一定程度上缓解症状而不能根治。 At present, the treatment of vasculitis often uses vasodilator drugs and anti-inflammatory drugs. Because the medical community's formation mechanism of vasculitis is not clear, the medication can only relieve symptoms to a certain extent and cannot be cured.
对发明的公开 Disclosure of invention
技术问题 technical problem
发明所要解决的技术问题在于提供一种盐酸在制备治疗胃炎药物中的应用。 本发明所要解决的技术问题在于提供一种盐酸在制备治疗胃炎药物中的应用。 本发明所要解决的技术问题还在于提供一种盐酸在制备治疗肠炎药物中的应用 本发明所要解决的技术问题还在于提供一种盐酸在制备治疗脉管炎药物中的应 用。 [19] 不受特定理论的限制, 本发明人发现胃炎、 肠炎和脉管炎的形成基于以下机理 : 食物在胃内消化, 产生大量的有机酸、 碳酸和氢离子 (H+) , 统称为胃酸。 胃壁细胞的细胞膜表面的黏液和脂类物质吸附胃内的碳酸 (H2C03) , 形成无机 酸的保护层, 该保护层保护胃壁不受胃内消化食物吋产生的有机酸的侵蚀。 同 理, 肠壁上的黏液和脂类物质吸附肠内的碳酸 (H2C03) , 形成无机酸保护层; 血管壁上的黏液和脂类物质吸附血管内的碳酸 (H2C03) , 形成无机酸保护层。 The technical problem to be solved by the invention is to provide a use of hydrochloric acid in the preparation of a medicament for treating gastritis. The technical problem to be solved by the present invention is to provide a use of hydrochloric acid in the preparation of a medicament for treating gastritis. The technical problem to be solved by the present invention is to provide a use of hydrochloric acid in the preparation of a medicament for treating enteritis. The technical problem to be solved by the present invention is to provide a use of hydrochloric acid in the preparation of a medicament for treating vasculitis. [19] Without being bound by a particular theory, the inventors have discovered that the formation of gastritis, enteritis, and vasculitis is based on the following mechanisms: Food is digested in the stomach, producing large amounts of organic acids, carbonic acid, and hydrogen ions (H+), collectively referred to as gastric acid. . Mucus and lipid membrane surface of the gastric parietal cells of the stomach carbonate adsorption (H 2 C0 3), an inorganic acid forming the protective layer, the protective layer protects the stomach from gastric digestion of food organic acids produced inch erosion. Similarly, the mucus and lipids on the intestinal wall absorb the carbonic acid (H 2 C0 3 ) in the intestine to form a protective layer of inorganic acid; the mucus and lipids on the blood vessel wall adsorb carbonic acid (H 2 C0 3 ) in the blood vessel. , forming a protective layer of inorganic acid.
[20] 体内的黏液和脂类物质对无机酸的吸附能力存在个体差异, 该吸附能力也会随 人体机能的下降而衰退。 当人体对无机酸保护层的吸附能力下降吋, 无机酸保 护层就易被胃肠及血管内的有机酸所取代, 从而有机酸直接与胃壁、 肠壁、 血 管壁接触, 这样就造成了对胃、 肠、 血管壁的侵蚀。 被腐蚀的胃壁就会发炎, 就形成了胃炎。 轻者为浅表性胃炎, 当胃壁严重腐蚀、  [20] There are individual differences in the ability of mucus and lipids to adsorb inorganic acids in the body, and this adsorption capacity also declines as the body functions decline. When the body's adsorption capacity to the inorganic acid protective layer is reduced, the inorganic acid protective layer is easily replaced by organic acids in the gastrointestinal and intravascular blood, so that the organic acid directly contacts the stomach wall, the intestinal wall, and the blood vessel wall, thus causing Erosion of the stomach, intestines, and blood vessel walls. The corroded stomach wall is inflamed and forms gastritis. Light is superficial gastritis, when the stomach wall is severely corroded,
糜烂就形成了萎缩性胃炎。 同理, 有机酸对肠壁的侵蚀造成了肠炎, 有机酸对 血管壁的侵蚀造成了脉管炎。  Atrophic gastritis is formed by erosion. In the same way, the erosion of the intestinal wall by organic acids causes enteritis, and the erosion of the blood vessel wall by organic acids causes vasculitis.
[21] 基于上述机理, 发明人经过潜心研究发现, 盐酸是最理想的形成无机酸保护层 的物质。 [21] Based on the above mechanism, the inventors have found through enthusiasm that hydrochloric acid is the most ideal material for forming a protective layer of inorganic acid.
[22] 因此, 在本发明的第一方面, 提供了一种盐酸在制备治疗胃炎药物中的应用。  [22] Therefore, in a first aspect of the invention, there is provided a use of hydrochloric acid for the preparation of a medicament for treating gastritis.
[23] 在本发明的第二方面, 提供了一种盐酸在制备治疗肠炎药物中的应用。 [23] In a second aspect of the invention, there is provided a use of hydrochloric acid for the preparation of a medicament for the treatment of enteritis.
[24] 在本发明的第三方面, 提供了一种盐酸在制备治疗脉管炎药物中的应用。 [24] In a third aspect of the invention, there is provided a use of hydrochloric acid for the manufacture of a medicament for treating vasculitis.
[25] 本发明的盐酸用于治疗胃炎、 肠炎、 脉管炎的机理在于: 盐酸为强无机酸, 胃 壁、 肠壁和血管壁上的黏液和脂类物质吸附盐酸的能力远胜于吸附碳酸的能力 , 因而釆用盐酸治疗吋, 盐酸在胃壁、 肠壁和血管壁上生成强吸附的无机酸保 护层, 该无机酸保护层不易被有机酸取代, 同吋盐酸还对受损处起到了杀菌消 炎的作用。 无机酸可以保护机体, 而有机酸侵蚀机体的结论可以从下述事实上 得以说明: 用含有无机酸 (盐酸) 的水溶液和含有有机酸 (醋酸等) 的水溶液 (两者的水溶液的 pH值相等) 分别擦洗皮肤, 无机酸的水溶液使皮肤湿润光滑 , 达到保护美容皮肤的作用, 而使用有机酸的水溶液擦洗几次后, 皮肤粗糙受 到了侵蚀。 这可以从一定程度上说明, 当有机酸直接与人体表面、 器官内壁和 血管内壁直接接触, 就会被侵蚀、 破坏, 而无机酸相反却可以起到保护作用。 [26] 本发明所述盐酸用于制备治疗胃炎、 肠炎、 脉管炎药物吋, 通常所述的药物为 含有盐酸的水溶液, 优选地, 所述水溶液的 pH控制在 1.5〜6.9, 再优选地, 所述 水溶液的 pH控制在 4〜6.5。 [25] The mechanism of the hydrochloric acid of the present invention for treating gastritis, enteritis and vasculitis is as follows: Hydrochloric acid is a strong inorganic acid, and the ability of mucus and lipid substances on the stomach wall, intestinal wall and blood vessel wall to adsorb hydrochloric acid is much better than adsorption of carbonic acid. The ability to treat sputum with hydrochloric acid, hydrochloric acid on the stomach wall, intestinal wall and blood vessel wall to form a strong adsorption of inorganic acid protective layer, the inorganic acid protective layer is not easily replaced by organic acid, the same hydrochloric acid also played a role in the damage The role of sterilization and anti-inflammatory. The inorganic acid can protect the body, and the conclusion that the organic acid erodes the body can be explained from the following: An aqueous solution containing a mineral acid (hydrochloric acid) and an aqueous solution containing an organic acid (such as acetic acid) (the pH of the aqueous solution is equal) The skin is scrubbed separately, and the aqueous solution of inorganic acid moisturizes the skin to protect the skin. After scrubbing several times with an aqueous solution of organic acid, the skin is roughened. This can explain to some extent that when the organic acid directly contacts the human body surface, the inner wall of the organ and the inner wall of the blood vessel, it will be eroded and destroyed, while the inorganic acid can protect it. [26] The hydrochloric acid of the present invention is used for preparing a drug for treating gastritis, enteritis, and vasculitis. Generally, the drug is an aqueous solution containing hydrochloric acid. Preferably, the pH of the aqueous solution is controlled at 1.5 to 6.9, and more preferably The pH of the aqueous solution is controlled to be 4 to 6.5.
[27] 进一步, 所述水溶液的 pH控制在 6.5〜6.9。 据国家饮用水标准, 饮用水的 pH应 该为 6.5〜8.5, 因而只要控制上述水溶液的 pH在 6.5〜6.9, 就可以将所述的含有 盐酸的水溶液作为食用盐酸水直接饮用。 [27] Further, the pH of the aqueous solution is controlled to be 6.5 to 6.9. According to the national drinking water standard, the pH of drinking water should be 6.5 to 8.5. Therefore, as long as the pH of the aqueous solution is controlled to be 6.5 to 6.9, the aqueous solution containing hydrochloric acid can be directly consumed as edible hydrochloric acid water.
[28] 所述药物均可以用于制备口服液或注射剂以及其它剂型, 作为治疗作用的盐酸 水溶液在食用治疗胃炎、 肠炎、 脉管炎吋, 每日饮用一般控制在 1000〜3000ml , 分为 3〜6次饮用, 3〜6个月为一疗程。 在注射用治疗胃炎、 肠炎、 脉管炎吋 , 每日的推荐用量为 500ml, 分两次注射, 静脉滴注, 连续 2〜3个月为一疗程。 按上述用法及用量治疗胃炎、 肠炎、 脉管炎, 一年后一般服药数量可减半, 二 年后基本康复。 [28] The drugs can be used for the preparation of oral liquid or injection and other dosage forms, as a therapeutic aqueous solution of hydrochloric acid in the treatment of gastritis, enteritis, vasculitis, daily drinking is generally controlled at 1000~3000ml, divided into 3 ~6 times to drink, 3 to 6 months for a course of treatment. In the treatment of gastritis, enteritis, vasculitis, the recommended daily dose is 500ml, divided into two injections, intravenous drip, for 2 to 3 months for a course of treatment. According to the above usage and dosage, gastroenteritis, enteritis and vasculitis can be treated. After one year, the general dose can be halved, and after two years, basic rehabilitation.
[29] 可以按如下方法人工配制口服液: 盐酸加入饮用水中搅拌均匀, 灌装灭菌前精 确检测 pH值, 将 pH值控制在 1.5〜6.9; 食用盐酸水的 pH控制在 6.5〜6.9。  [29] The oral solution can be artificially prepared as follows: Hydrochloric acid is added to the drinking water and stirred evenly. The pH value is accurately detected before filling and sterilizing, and the pH is controlled at 1.5 to 6.9; the pH of the edible hydrochloric acid is controlled at 6.5 to 6.9.
[30] 工业法配制吋, 可以釆用 pH值控制装置来进行连续、 稳定、 大批量地制备上述 含有盐酸的水溶液。 [30] In the industrial process, a pH control device can be used to continuously, stably and in large quantities prepare the above aqueous solution containing hydrochloric acid.
[31] 可以由盐酸按药学上通常的方法制备注射剂, 只要控制注射剂 pH在 1.5〜6.9即 可。  [31] An injection can be prepared from hydrochloric acid in a pharmaceutically usual manner as long as the pH of the injection is controlled to be 1.5 to 6.9.
[32] 釆用自来水制造盐酸水吋, 一般应该在前端设置净化装置使其达到国家饮用水 的卫生标准。  [32] 自 Hydrochloric acid hydrazine is made from tap water. Generally, a purification device should be installed at the front end to meet the national sanitary standard for drinking water.
[33] 为了达到治疗胃炎、 肠炎、 脉管炎的目的, 本发明所述的盐酸也可以应用于其 它溶液中, 如生理盐水、 葡萄糖溶液、 饮料等, 其配制盐酸水的方法同上, 只 要控制口服液或注射剂的 pH即可。  [33] In order to achieve the purpose of treating gastritis, enteritis, vasculitis, the hydrochloric acid of the present invention can also be applied to other solutions, such as physiological saline, glucose solution, beverage, etc., and the method for preparing hydrochloric acid water is the same as above, as long as control The pH of the oral solution or the injection can be used.
[34] 本发明所述的食用盐酸水一般不允许加热饮用, 因为加热会使盐酸挥发而失去 疗效。 也不要饮容易结垢的饮料、 茶水和碱性保健品, 茶碱及碱性物质易与盐 酸中和而使本盐酸水溶液失去作用。 [34] The edible hydrochloric acid water according to the present invention generally does not allow heating to be consumed, because heating causes the hydrochloric acid to volatilize and loses its therapeutic effect. Do not drink beverages, tea and alkaline health products that are prone to scaling. Theophylline and alkaline substances are easily neutralized with hydrochloric acid to disable the aqueous hydrochloric acid solution.
[35] 为说明本发明所述的盐酸对胃炎、 肠炎、 脉管炎的治疗效果, 本发明对 1060例 饮用食用盐酸水的胃炎、 肠炎患者进行了临床观察, 其中胃炎患者 500例, 肠炎 患者 400例, 脉管炎 160例, 男 560例, 女 500例, 平均年龄 59岁, 年龄范围 28〜7[35] In order to illustrate the therapeutic effect of the hydrochloric acid of the present invention on gastritis, enteritis, vasculitis, the present invention has clinically observed 1060 patients with gastritis and enteritis drinking drinking hydrochloric acid, wherein 500 patients with gastritis, enteritis 400 patients, 160 patients with vasculitis, 560 males and 500 females, with an average age of 59 years, age range 28~7
2岁。 2 years old.
[36] 使用结果表明: 服用二年后,食用盐酸水配合药物治疗胃炎患者和完全饮用食用 盐酸水治疗胃炎患者并已痊愈的 370例,  [36] The results of the use showed that: After taking the two years, 370 cases of patients with gastritis treated with hydrochloric acid water and drugs and completely treated with hydrochloric acid water have been cured.
90例由萎缩性胃炎转换为浅表性胃炎, 40例胃药停服, 腹痛现象消失; 食用盐 酸水配合药物治疗肠炎患者和完全饮用食用盐酸水治疗肠炎患者并已痊愈的 350 例, 50例症状减轻; 食用盐酸水配合药物治疗脉管炎患者和完全饮用食用盐酸 水治疗脉管炎患者并已痊愈的 130例, 30例症状减轻。 总有效率 100%。  90 cases were converted from atrophic gastritis to superficial gastritis, 40 cases of gastric medicine stopped taking, and abdominal pain disappeared. 350 cases of 50 cases, 50 cases of patients with enteritis treated with hydrochloric acid and drugs and completely drinking hydrochloric acid Symptoms were alleviated; 130 patients with vasculitis treated with hydrochloric acid combined with drugs and completely treated with hydrochloric acid for the treatment of vasculitis were cured, and 30 symptoms were alleviated. The total effective rate is 100%.
[37] 本发明所述的盐酸制备制得的药物治疗胃炎、 肠炎、 脉管炎安全可靠, 有着确 切、 明显的效果。 [37] The medicament prepared by the hydrochloric acid preparation of the invention is safe and reliable for treating gastritis, enteritis and vasculitis, and has a certain and obvious effect.
本发明的实施方式  Embodiments of the invention
[38] 下面结合实施例对本发明作进一步说明, 但本发明的保护范围并不限于此。  [38] The present invention will be further described below in conjunction with the embodiments, but the scope of protection of the present invention is not limited thereto.
[39] 实施例 1 [39] Example 1
[40] 将高纯度稀盐酸加入饮用水中搅拌均匀, 精确控制 pH值为 6.5〜6.9, 可直接服 用。  [40] Add high-purity dilute hydrochloric acid to drinking water and mix well. Precisely control the pH value of 6.5~6.9, which can be used directly.
[41] 实施例 2  [41] Example 2
[42] 将高纯度盐酸加入饮用水中稀释至 2%的盐酸溶液, 灌装于带有流量控制器的 盐酸溶液中。 将上述盐酸溶液和饮用水以一定流量比经管道混合, 所述管道末 端设置 pH值检测器。 控制盐酸水溶液 pH在 6.5〜6.9, 制得食用盐酸水。  [42] Add high-purity hydrochloric acid to a hydrochloric acid solution diluted to 2% in drinking water and fill it in a hydrochloric acid solution with a flow controller. The hydrochloric acid solution and the drinking water are mixed at a certain flow ratio through a pipe, and a pH detector is disposed at the end of the pipe. The hydrochloric acid aqueous solution was controlled to have a pH of 6.5 to 6.9 to prepare edible hydrochloric acid water.
[43] 应用例 1  [43] Application example 1
[44] 釆用上述制得食用盐酸水对 16例胃炎患者进行治疗观察, 患者每日饮用 2000ml [44] 16 Treating 16 patients with gastritis with the edible hydrochloric acid prepared above, the patient was given 2000ml daily.
, 早、 中餐前一小吋各饮 500ml, 晚餐前一小吋饮 1000ml。 In the morning, before the Chinese food, drink 500ml each, and drink a little 1000ml before dinner.
[45] 表 1为饮用本发明所述食用盐酸水后病例的胃炎病情改善情况。 [45] Table 1 shows the improvement of gastritis in cases after drinking the edible hydrochloric acid water of the present invention.
[46] 表 1食用盐酸水治疗胃炎 患者编号 原症状 年龄 胃炎的治疗效果 [46] Table 1 consumption of hydrochloric acid water for the treatment of gastritis Patient number of the original symptoms of age gastritis
1 浅表性胃炎 28 10个月痊愈  1 superficial gastritis 28 10 months cured
2 浅表性胃炎 34 一年痊愈  2 superficial gastritis 34 one year healed
3 浅表性胃炎 56 一年半痊愈  3 superficial gastritis 56 one and a half year healed
4 浅表性胃炎 56 一年半痊愈  4 superficial gastritis 56 one and a half year healed
5 浅表性胃炎 38 一年痊愈  5 superficial gastritis 38 one year healed
6 浅表性胃炎 57 一年半痊愈  6 superficial gastritis 57 one and a half year healed
7 浅表性胃炎 67 二年痊愈  7 superficial gastritis 67 recovered in two years
8 浅表性胃炎 55 一年半痊愈  8 superficial gastritis 55 one and a half year healed
9 浅表性胃炎 57 一年半痊愈  9 superficial gastritis 57 one and a half year healed
10 萎缩性胃炎 68 二年半后转为浅表性胃炎  10 Atrophic gastritis 68 After two and a half years, it turned into superficial gastritis
11 萎缩性胃炎 69 二年后转为浅表性胃炎  11 Atrophic gastritis 69 After two years, it turned into superficial gastritis
12 萎缩性胃炎 56 二年痊愈  12 atrophic gastritis 56 two years of recovery
13 萎缩性胃炎 58 三年痊愈  13 atrophic gastritis 58 three years of recovery
14 萎缩性胃炎 67 二年后转为浅表性胃炎  14 Atrophic gastritis 67 After two years, it turned into superficial gastritis
15 萎缩性胃炎 66 二年后转为浅表性胃炎  15 Atrophic gastritis 66 After two years, it turned into superficial gastritis
16 萎缩性胃炎 76 二年后转为浅表性胃炎  16 Atrophic gastritis 76 After two years, it turned into superficial gastritis
[47]  [47]
[48] 应用例 2 [48] Application example 2
[49] 釆用上述制得食用盐酸水对 16例肠炎患者进行治疗观察, 患者每日饮用 2000ml [49] 16 Treatment of 16 cases of enteritis with the edible hydrochloric acid prepared above, the patient consumed 2000ml daily
, 早、 中餐前一小吋各饮 500ml, 晚餐前一小吋饮 1000ml。 In the morning, before the Chinese food, drink 500ml each, and drink a little 1000ml before dinner.
[50] 表 2为饮用本发明所述食用盐酸水后病例的肠炎病情改善情况。  [2] Table 2 shows the improvement of enteritis in cases after drinking the edible hydrochloric acid water of the present invention.
[51] 表 2食用盐酸水治疗肠炎  [51] Table 2 consumption of hydrochloric acid water for the treatment of enteritis
[52] 患者编 原症状 年龄 肠炎的治疗效果 [52] Therapeutic effect of patients with original symptoms of age-induced enteritis
 number
1 肠炎 30 一年后痊愈  1 Enteritis 30 Healed after one year
2 肠炎 34 一年后痊愈  2 Enteritis 34 Healed after one year
3 肠炎 54 二年后痊愈  3 Enteritis 54 Healed after two years
4 肠炎 55 二年后痊愈  4 Enteritis 55 Healed after two years
5 肠炎 38 一年后痊愈  5 Enteritis 38 Healed after one year
6 肠炎 60 二年后痊愈  6 enteritis 60 recovered after two years
7 肠炎 67 二年后痊愈  7 Enteritis 67 Healed after two years
8 肠炎 55 一年后痊愈  8 Enteritis 55 Healed after one year
9 肠炎 58 一年后痊愈  9 Enteritis 58 Healed after one year
10 肠炎 68 二年后症状明显减轻  10 enteritis 68 symptoms are significantly reduced after two years
11 肠炎 69 二年后症状明显减轻  11 enteritis 69 symptoms are significantly reduced after two years
12 肠炎 55 一年后痊愈  12 Enteritis 55 Healed after one year
13 肠炎 57 一年后痊愈  13 Enteritis 57 Healed after one year
14 肠炎 67 二年后症状明显减轻  14 enteritis 67 symptoms are significantly reduced after two years
15 肠炎 66 二年后症状明显减轻  15 enteritis 66 symptoms are significantly reduced after two years
16 肠炎 74 二年后症状明显减轻  16 enteritis 74 symptoms are significantly reduced after two years
[53] 应用例 3 [53] Application example 3
[54] 釆用上述制得食用盐酸水对 16例脉管炎患者进行治疗观察, 患者每日饮用 2000 ml, 早、 中餐前一小吋各饮 500ml, 晚餐前一小吋饮 1000ml。  [54] 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16 16
[55] 表 3为饮用本发明所述食用盐酸水后病例的脉管炎病情改善情况。 [55] Table 3 shows the improvement of vasculitis in cases after drinking the edible hydrochloric acid water of the present invention.
[56] 表 3食用盐酸水治疗脉管炎 患者编号原症状 年龄 治疗效果 [56] Table 3 consumption of hydrochloric acid water treatment of vasculitis Patient number original symptom age treatment effect
1 脉管炎 30 一年后痊愈 1 vasculitis 30 recovered after one year
2 脉管炎 34 一年后痊愈  2 vasculitis 34 recovered after one year
3 脉管炎 54 二年后痊愈  3 vasculitis 54 recovered after two years
4 脉管炎 55 二年后痊愈  4 vasculitis 55 recovered after two years
5 脉管炎 38 一年后痊愈  5 vasculitis 38 recovered after one year
6 脉管炎 60 二年后痊愈  6 vasculitis 60 recovered after two years
7 脉管炎 67 二年后痊愈  7 vasculitis 67 recovered after two years
8 脉管炎 55 一年后痊愈  8 vasculitis 55 recovered after one year
9 脉管炎 58 一年后痊愈  9 vasculitis 58 recovered after one year
10 脉管炎 68 二年后症状明显减轻  10 vasculitis 68 symptoms are significantly reduced after two years
11 脉管炎 69 二年后症状明显减轻  11 vasculitis 69 symptoms are significantly reduced after two years
12 脉管炎 55 一年后痊愈  12 vasculitis 55 recovered after one year
13 脉管炎 57 一年后痊愈  13 vasculitis 57 recovered after one year
14 脉管炎 67 二年后症状明显减轻  14 vasculitis 67 symptoms are significantly reduced after two years
15 脉管炎 66 二年后症状明显减轻  15 vasculitis 66 symptoms are significantly reduced after two years
16 脉管炎 74 二年后症状明显减轻 由表 1、 表 2、 表 3可以看出, 盐酸水溶液用于治疗胃炎、 肠炎、 脉管炎疗效明 显, 总有效率 100%。  16 vasculitis 74 Significant relief after two years From Table 1, Table 2, Table 3, it can be seen that the aqueous solution of hydrochloric acid is effective in the treatment of gastritis, enteritis and vasculitis, and the total effective rate is 100%.

Claims

权利要求书 Claim
1、 盐酸在制备治疗胃炎药物中的应用。  1. The application of hydrochloric acid in the preparation of a medicament for treating gastritis.
2、 如权利要求 1所述的盐酸在制备治疗胃炎药物中的应用, 其特征在于所 述的药物为含有盐酸的水溶液, 所述水溶液的 pH控制在 1.5〜6.9。  The use of hydrochloric acid according to claim 1 for the preparation of a medicament for treating gastritis, characterized in that the medicament is an aqueous solution containing hydrochloric acid, and the pH of the aqueous solution is controlled to be 1.5 to 6.9.
3、 如权利要求 2所述的盐酸在制备治疗胃炎药物中的应用, 其特征在于所 述水溶液的 pH控制在 4〜6.5。  The use of hydrochloric acid according to claim 2 for the preparation of a medicament for treating gastritis, characterized in that the pH of the aqueous solution is controlled at 4 to 6.5.
4、 如权利要求 2所述的盐酸在制备治疗胃炎药物中的应用, 其特征在于所 述水溶液的 pH控制在 6.5〜6.9。  The use of hydrochloric acid according to claim 2 for the preparation of a medicament for treating gastritis, characterized in that the pH of the aqueous solution is controlled at 6.5 to 6.9.
5、 盐酸在制备治疗肠炎药物中的应用。  5. The application of hydrochloric acid in the preparation of a medicament for treating enteritis.
6、 如权利要求 5所述的盐酸在制备治疗肠炎药物中的应用, 其特征在于所 述的药物为含有盐酸的水溶液, 所述水溶液的 pH控制在 1.5〜6.9。  The use of hydrochloric acid according to claim 5 for the preparation of a medicament for treating enteritis, characterized in that the medicament is an aqueous solution containing hydrochloric acid, and the pH of the aqueous solution is controlled to be 1.5 to 6.9.
7、 如权利要求 6所述的盐酸在制备治疗肠炎药物中的应用, 其特征在于所 述水溶液的 pH控制在 4〜6.5。  7. Use of hydrochloric acid according to claim 6 for the preparation of a medicament for the treatment of enteritis, characterized in that the pH of the aqueous solution is controlled between 4 and 6.5.
8、 如权利要求 6所述的盐酸在制备治疗肠炎药物中的应用, 其特征在于所 述水溶液的 pH控制在 6.5〜6.9。  The use of hydrochloric acid according to claim 6 for the preparation of a medicament for the treatment of enteritis, characterized in that the pH of the aqueous solution is controlled at 6.5 to 6.9.
9、 盐酸在制备治疗脉管炎药物中的应用。  9. The application of hydrochloric acid in the preparation of a medicament for treating vasculitis.
10、 如权利要求 9所述的盐酸在制备治疗脉管炎药物中的应用, 其特征在于 所述的药物为含有盐酸的水溶液, 所述水溶液的 pH控制在 1.5〜6.9。  The use of hydrochloric acid according to claim 9 for the preparation of a medicament for treating vasculitis, characterized in that the medicament is an aqueous solution containing hydrochloric acid, and the pH of the aqueous solution is controlled to be 1.5 to 6.9.
PCT/CN2008/071708 2008-07-21 2008-07-21 Use of hydrochloric acid for the manufacture of a medicament for treatment of gastritis, enteritis and angiitis WO2010009589A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2008/071708 WO2010009589A1 (en) 2008-07-21 2008-07-21 Use of hydrochloric acid for the manufacture of a medicament for treatment of gastritis, enteritis and angiitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2008/071708 WO2010009589A1 (en) 2008-07-21 2008-07-21 Use of hydrochloric acid for the manufacture of a medicament for treatment of gastritis, enteritis and angiitis

Publications (1)

Publication Number Publication Date
WO2010009589A1 true WO2010009589A1 (en) 2010-01-28

Family

ID=41569989

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2008/071708 WO2010009589A1 (en) 2008-07-21 2008-07-21 Use of hydrochloric acid for the manufacture of a medicament for treatment of gastritis, enteritis and angiitis

Country Status (1)

Country Link
WO (1) WO2010009589A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1830454A (en) * 2005-03-10 2006-09-13 刘智仁 Application of hydrochloric acid in preparation of medicine for treating high blood pressure
CN101138568A (en) * 2006-09-08 2008-03-12 刘智仁 Application of hydrochloric acid in the preparation of medicament for treating diabetes and prostate gland disease
CN101224223A (en) * 2007-01-15 2008-07-23 刘智仁 Application of HCl in preparing medicine for treating gastritis, enteritis and vasculitis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1830454A (en) * 2005-03-10 2006-09-13 刘智仁 Application of hydrochloric acid in preparation of medicine for treating high blood pressure
CN101138568A (en) * 2006-09-08 2008-03-12 刘智仁 Application of hydrochloric acid in the preparation of medicament for treating diabetes and prostate gland disease
CN101224223A (en) * 2007-01-15 2008-07-23 刘智仁 Application of HCl in preparing medicine for treating gastritis, enteritis and vasculitis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Ten methods for the treatment of chronic atrophic gastritis", FOR YOUR HEALTH, no. 8, 1995, pages 12 *
JIANG YANGQING: "Use of acidic Chinese Medicine in the treatment of atrophic gastritis", CHINESE COMMUNITY DOCTORS, no. 3, 1991, pages 19 *
WEI BANGFU: "Dialectically select drugs to aid digestion", MEDICINE HEALTH CARE, no. 9, 2006, pages 49 *

Similar Documents

Publication Publication Date Title
JP2007051134A (en) Utilization of d-allose and d-psicose for anti-neurogenic pain effect
CN1772164A (en) Medicine for treating chronic constipation
KR101488921B1 (en) Mint liquid for improving digestive functions and manufacturing method thereof
KR101808328B1 (en) Composition for improvement and prevention of gastroesophageal reflux disease and method for preparing the same
WO2010009589A1 (en) Use of hydrochloric acid for the manufacture of a medicament for treatment of gastritis, enteritis and angiitis
CN104857454B (en) A kind of traditional Chinese herbal decoction for treating Severe Acute Pancreatitis SAP
CN107441470A (en) A kind of Chinese medicine for treating stomach cold
CN101224223A (en) Application of HCl in preparing medicine for treating gastritis, enteritis and vasculitis
CN104127668A (en) Traditional Chinese medicinal preparation for curing chronic pharyngitis
CN102920764A (en) Application of inula cappa in preparation of medicine used for preventing amygdalitis
CN103142704B (en) Functional white wine for treating constipation, insomnia and gout, lowering blood sugar and tonifying yang
CN102697859A (en) Traditional Chinese medicine for treating cholecystitis
CN107412422A (en) A kind of oral liquid that can improve body regulatory function
JP6184960B2 (en) New uses for melatonin
CN107913402A (en) A kind of combination of Chinese tradiational and Western medicine medicine for treating atrophic gastritis and preparation method
CN106389962A (en) Traditional Chinese medicinal composition for preventing and treating lamb colibacillosis, and preparation method and application thereof
CN106421220A (en) Preparation method for marine biological wound-healing spraying-membrane agent
WO2008047853A1 (en) Prophylactic/therapeutic agent for gastroesophageal reflux disease
Yulan et al. Analysis Review of Clinical Application Research of Sanwu Beiji Wan
CN103040065B (en) Apple vinegar beverage for treating and preventing hiccups and preparation method thereof
CN105748700B (en) Treat the externally used Mongolian medicine preparation of ulcerative colitis
CN103341077B (en) Chinese herbal preparation with effects of regulating vital energy and relaxing bowels and preparation method of Chinese herbal preparation
CN104258273A (en) Traditional Chinese medicine for treating gastric ulcer
CN107184925A (en) Treat the Chinese medicine composition of chronic pharyngitis
CN104381450A (en) Health milk for treatment of gastric mucosal injury and preparation method thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08773229

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08773229

Country of ref document: EP

Kind code of ref document: A1